الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common
type of lymphoma and is highly heterogeneous in regard to clinical
manifestations, biological features, and prognosis. The introduction of
rituximab (R) combined with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) has resulted in improved outcome
in DLBCL patients; however, variable prognosis is present and
identifying distinct subsets for therapeutic decisions is essential
(Vaidya and Witzig, 2014).
MicroRNAs (miRNAs), such as miR-150, are 20- to 24-
nucleotide noncoding RNAs found in animals and plants. These small
RNAs regulate gene expression at the translational level through
interactions with their target mRNAs. MiR-150 is a hematopoietic cell-
specific miRNA (Zhou et al., 2007).
MiR-21 is one of the first human miRNA genes whose regulation
was extensively studied and indeed, miR-21 is an example of an
intronic miRNA. Despite that, primiR-21 has its own promoter region
(Cai et al., 2004).
The current study was carried out at Medical Biochemistry and
Molecular Biology department and Clinical Oncology and Nuclear
Medicine department, Faculty of Medicine, Menoufia University.
We aimed to study serum miR-150 and miR-21 in patients with
Diffuse Large B Cell Lymphoma as diagnostic and prognostic markers.